• Français

Centre de recherche
Monday, December 19 2011
Press release

Novel use of drug saves children from deadly E. coli bacteria disease

Montreal, Canada, December 19, 2011 – A physician and researcher at the Sainte Justine University Hospital Center (Sainte-Justine UHC), a University of Montreal affiliate, saved the life of a child and, by doing so, became the first to find a new use for a drug in the fight against deadly E. coli bacteria. In fact, after a little girl was admitted to the Sainte Justine UHC to treat severe complications, her physician, running out of options, thought about using the drug eculizumab, which is usually prescribed for another disorder with similar symptoms. Her intuition paid off and the little girl survived. The dramatic improvement experienced by the young patient and two others is explained in an article published last summer in the New England Journal of Medicine.

“At the time, there was no recognized treatment to cure the hemolytic and uremic syndrome, a severe complications associated with E. coli infections,” says Dr. Anne-Laure Lapeyraque, a nephrologist in the Department of Pediatrics at the Sainte Justine UHC as well as a professor at the University of Montreal. “Successful use of this medication in these children has opened our eyes to a promising new treatment.”

Dr. Anne-Laure Lapeyraque and her international colleagues relate how eculizumab was used to treat three 3-year-olds with E. coli-related neurological complications. Within a few days to weeks, their blood counts returned to normal and their kidneys recovered. Eculizumab, a drug known as a monoclonal antibody, acts by blocking a substance in the immune system known as complement protein C5.

Once this new drug application had been discovered, intravenous eculizumab therapy was used to save the lives of a large number of people. “Our report was published during the massive E. coli outbreak in May and June in Germany, which allowed us to break the news and alert physicians,” explains Dr. Lapeyraque. During the outbreak, about 4,000 people in Europe fell ill by eating contaminated sprouts.

E. coli infection with a Shiga toxin-producing strain (“hamburger disease”) has been the subject of several recalls of contaminated beef in Canada and the United States over the past few years. E. coli can be found in undercooked ground beef, unpasteurized (raw) dairy products and contaminated fruits and vegetables, particularly alfalfa sprouts. Symptoms include cramps and vomiting, with or without bloody diarrhea, and can lead to kidney failure and be life threatening. This is why it is important to cook hamburger meat thoroughly, wash fruits and vegetables, avoid unpasteurized dairy products, especially for children, and wash one’s hands after handling raw meat. According to Dr. Lapeyraque, these precautions have greatly reduced the incidence of E. coli infection in Quebec.

The investigators on this international clinical team are very excited about their discovery. For one thing, it helps explain how and why hamburger disease can develop with such devastating consequences. “Further research studies are needed to determine which patients will benefit from it the most,” adds Dr. Lapeyraque. In any event, “eculizumab” is now a hot buzzword at kidney disease meetings around the world.

– 30 –


About the study:
Eculizumab in severe Shiga-toxin-associated HUS” was published in the New England Journal of Medicine online on May 25 and in print in the June 30, 2011 issue. The authors are Anne-Laure Lapeyraque, Michal Malina, Véronique Fremeaux-Bacchi, Tobias Boppel, Michael Kirschfink, Mehdi Oualha, François Proulx, Marie-José Clermont, Françoise Le Deist, Patrick Niaudet, and Franz Schaefer.

About the CHU Sainte-Justine Research Center
The CHU Sainte-Justine Research Center is a leading mother-child research institution affiliated with Université de Montréal. It brings together more than 1200 people, including over 200 researchers and clinician-researchers and 450 graduate and post-graduate students who carry out fundamental, clinical, and evaluative research on maternal and child health. Research work falls under six research axes, namely Health Outcomes; Brain Diseases; Musculoskeletal Diseases and Movement Sciences; Viral and Immune Disorders and Cancers; Fetomaternal and Neonatal Pathologies; and Metabolic Health. It is focused on finding innovative prevention means, faster and less invasive treatments, as well as personalized approaches to medicine. The Center is part of the Sainte-Justine University Hospital Centre, which is the largest mother-child centre in Canada and one of the four most important pediatric centres in North America. For more information, please visit www.chu-sainte-justine.org/research/

About this page
Updated on 11/17/2014
Created on 11/17/2014
Alert or send a suggestion

Every dollar counts!

Thank you for your generosity.

It's people like you that allow us to accelerate research and heal more children better every year and, as such, offer among the best healthcare in the world.

It's also possible to give by mail or by calling toll-free

1-888-235-DONS (3667)

Contact Us

514 345-4931


© 2006-2014 CHU Sainte-Justine.
All rights reserved.
Terms of Use, Confidentiality, Security


Les informations contenues dans le site « CHU Sainte-Justine » ne doivent pas être utilisées comme un substitut aux conseils d’un médecin dûment qualifié et autorisé ou d’un autre professionnel de la santé. Les informations fournies ici le sont à des fins exclusivement éducatives et informatives.

Consultez votre médecin si vous croyez être malade ou composez le 911 pour toute urgence médicale.

CHU Sainte-Justine